Inogen (INGN) Competitors

Bioventus (NYSE:BVS) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment.

Do analysts rate BVS or INGN?

Bioventus currently has a consensus target price of $15.00, indicating a potential upside of 79.04%. Inogen has a consensus target price of $7.00, indicating a potential upside of 2.47%. Given Bioventus' stronger consensus rating and higher possible upside, research analysts plainly believe Bioventus is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inogen	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has preferable valuation and earnings, BVS or INGN?

Inogen has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$573.28M	1.20	-$156.23M	-$0.51	-16.43
Inogen	$335.71M	0.55	-$102.45M	-$1.52	-4.49

Do institutionals and insiders believe in BVS or INGN?

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 32.9% of Bioventus shares are owned by insiders. Comparatively, 1.0% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is BVS or INGN more profitable?

Bioventus has a net margin of -7.11% compared to Inogen's net margin of -15.89%. Bioventus' return on equity of 15.61% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Inogen	-15.89%	-27.38%	-16.77%

Does the media favor BVS or INGN?

In the previous week, Bioventus had 1 more articles in the media than Inogen. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for Inogen. Bioventus' average media sentiment score of 1.49 beat Inogen's score of 0.51 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, BVS or INGN?

Bioventus has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.

Does the MarketBeat Community favor BVS or INGN?

Inogen received 358 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 68.97% of users gave Inogen an outperform vote while only 63.27% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
Bioventus	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%
Inogen	Outperform Votes 389 68.97%	Underperform Votes 175 31.03%

Summary

Bioventus beats Inogen on 12 of the 18 factors compared between the two stocks.